What is the guideline-directed medical management for non-obstructive cardiomyopathy?

Treatment of Non-Obstructive Cardiomyopathy

For symptomatic non-obstructive hypertrophic cardiomyopathy (HCM) with preserved ejection fraction, initiate beta blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem) as first-line therapy, and add low-dose diuretics if dyspnea persists despite optimal negative inotropic therapy. 1, 2

Initial Medical Management for Non-Obstructive HCM with Preserved EF

First-Line Therapy

• Beta blockers are the primary recommendation for symptomatic patients experiencing exertional angina or dyspnea 1, 2

  • Titrate to resting heart rate <60-65 bpm (up to maximum recommended doses) 3
  • Use cautiously in patients with sinus bradycardia or severe conduction disease 3

• Alternative: Non-dihydropyridine calcium channel blockers (verapamil or diltiazem) 1, 2

  • Use when beta blockers are ineffective, not tolerated, or contraindicated
  • Verapamil: start low dose, titrate up to 480 mg/day 3
  • Use with caution in patients with high gradients, advanced heart failure, or sinus bradycardia 3

Second-Line Therapy

• Add oral diuretics when exertional dyspnea persists despite beta blockers or calcium channel blockers 1, 2
  • Use cautiously and at low doses to avoid reducing preload excessively 4

Uncertain Benefit

• ACE inhibitors and ARBs: usefulness not well established for symptom management (angina/dyspnea) in non-obstructive HCM 1, 2

Important Caveat

For asymptomatic patients with non-obstructive HCM, the benefit of beta blockers or calcium channel blockers is not well established 1

---

Management When Systolic Dysfunction Develops (LVEF <50%)

If LVEF drops below 50%, immediately transition to standard guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction 5

Critical Actions:

1. Discontinue negative inotropic agents (verapamil, diltiazem, disopyramide) that were previously indicated 5

   • Exception: may continue if needed for rate/rhythm control of atrial fibrillation on case-by-case basis 1

2. Initiate HFrEF GDMT 5:

   • ARNI/ACE inhibitor/ARB
   • Beta blocker
   • Mineralocorticoid receptor antagonist (MRA)
   • SGLT2 inhibitor

3. Evaluate for other causes of systolic dysfunction (particularly coronary artery disease) 5

4. Consider ICD placement (Class 2a recommendation) 5

5. For NYHA class II-IV with LBBB: Consider cardiac resynchronization therapy (CRT) 5

---

Advanced Heart Failure Management

For NYHA class III-IV symptoms despite GDMT, perform cardiopulmonary exercise testing to quantify functional limitation and assess for heart transplantation 5

Transplant Evaluation Criteria:

• Non-obstructive HCM with advanced HF (NYHA III-IV despite GDMT) 5
• Life-threatening ventricular arrhythmias refractory to maximal therapy 5
• Note: Transplant referral for HCM does not require reduced EF due to restrictive physiology 1

Mechanical Circulatory Support:

• LVAD as bridge to transplant is reasonable for NYHA III-IV patients who are transplant candidates 5
• Better outcomes in patients with larger LV cavities (>46-50 mm) 1
• If patient decompensates while listed, evaluate for LVAD 5

---

Special Considerations

Takotsubo (Stress) Cardiomyopathy

If presenting with apparent acute coronary syndrome and non-obstructive coronary arteries at angiography, consider stress cardiomyopathy 6:

• Treat with conventional agents (ACE inhibitors, beta blockers, aspirin, diuretics) if hemodynamically stable 6
• Anticoagulation for LV thrombi 6
• Use catecholamines cautiously only if symptomatic hypotension without outflow tract obstruction 6
• IABP reasonable for refractory shock 6

Atrial Fibrillation Management

Anticoagulation is mandatory with direct oral anticoagulants (DOACs) as first-line, independent of CHA₂DS₂-VASc score 1, 2, 5

• For rate control: beta blockers, verapamil, or diltiazem 2, 5

---

Common Pitfalls to Avoid

1. Do NOT use dihydropyridine calcium channel blockers (nifedipine) in HCM—potentially harmful 3

2. Do NOT use digitalis for dyspnea in HCM patients without atrial fibrillation—potentially harmful 3

3. Do NOT use positive inotropes (dopamine, dobutamine, norepinephrine) for acute hypotension in obstructive HCM—potentially harmful 3

   • Use phenylephrine (pure vasoconstrictor) instead 3

4. Avoid aggressive diuresis—can worsen symptoms by reducing preload 4

5. Monitor cardiac myosin inhibitors (mavacamten): must discontinue if LVEF <50% 1

---

Emerging Therapies

Younger Patients with Mild Phenotype:

Valsartan may be beneficial to slow adverse cardiac remodeling in patients ≤45 years with non-obstructive HCM due to pathogenic sarcomere variant, NYHA I-II, maximal LV wall thickness 13-25 mm, no secondary prevention ICD, and no AF 1

Novel Agents Under Investigation:

Recent network meta-analysis 7 shows:

• Mavacamten: significantly reduced NT-proBNP (RoM 0.42,95% CI 0.32-0.56)
• ARNI and ninerafaxstat: improved VE/VCO₂ slope
• Candesartan: improved E/e' ratio
• However, no therapy demonstrated significant improvement in peak VO₂ (primary outcome)

This heterogeneity suggests targeting multiple pathophysiological pathways may be necessary, though larger head-to-head trials are needed 7.